NEW White Paper
Beyond the Barrier: Precision Preclinical Strategies for Targeting Glioblastoma
This white paper explores how integrated preclinical platforms—including orthotopic PDX models, humanized systems, and AI-driven predictive analytics—can bridge the gap between preclinical research and clinical success.
You Will Learn How To
- Select the right preclinical model: Compare cell lines, patient-derived cultures, PDX, and orthotopic systems for greater clinical relevance.
- Evaluate humanized and immunotherapy-ready systems: Examine GBM immune evasion and assess CAR-T and checkpoint inhibitor responses.
- Apply AI-driven predictive insights: Use CertisAI to forecast drug responses, identify synergistic combinations, and assess BBB penetration.
- Bridge the translational gap: Integrate multimodal endpoints, imaging, and molecular profiling to improve preclinical predictability.
Download White Paper
Your Translational Partner
Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Certis Oncology Intelligence® — highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our functional platform informs individual treatment and drug development decisions. Certis incorporates both 3D cell-based assays and in silico models to accelerate the development of new cancer therapies and reduce the number of animal models.